Vaccines Europe - 24 Feb 2022
Updated on March 1
As the war in Ukraine continues to cause unimaginable suffering, our first thoughts are with all those affected by this terrible act of aggression. The immediate priority for our industry is to ensure that patients continue to get access to the medicines they need. To support that aim, we would like to call on all parties to exclude medicines, active pharmaceutical ingredients and any other raw materials required to manufacture diagnostics, treatments and vaccines from the scope of sanctions.
We will continue to work with all parties to limit the impact of the war on the supply of medicines and vaccines to patients and on clinical trials which are a lifeline to so many patients across the region. We are actively exploring ways to ensure vital medicines reach the people who need them most and the health needs of the many thousands of people already displaced by the crisis are met.